A new colon cancer study at The James is taking a deeper look into hereditary colon cancer — specifically those caused by the genetic abnormality known as Lynch syndrome — and how a specific drug may help prevent the disease or its recurrence. One of the first studies to look at this high-risk population as well as new cancer treatments as a preventive measure, the study will hone in on the use of immunotherapies to prevent colon polyps that can lead to cancer, as well as second colon cancers, in patients with Lynch syndrome. If the study proves positive, it may mean that people with Lynch syndrome won’t develop these cancers at all because they're able to go on a preventative regimen.